Stem cells could offer new hope for severe eczema sufferers

NCT ID NCT04137562

Ongoing Disease control Sponsor: EHL Bio Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether a stem cell therapy called ADSTEM can safely and effectively treat moderate-to-severe atopic dermatitis (eczema). About 118 adults with long-lasting eczema that hasn't responded well to standard creams will receive either ADSTEM stem cells or a placebo via IV infusion. Researchers will track how many patients see at least a 50% improvement in their eczema symptoms over 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ADSTEM stem cells (mesenchymal stem cells) given by IV infusion
What this could lead to: If it works, this could lead to a new treatment option that helps control moderate-to-severe atopic dermatitis with fewer side effects than current therapies.
What could go wrong: This is an early Phase 2 trial with only 118 people, so results may not apply to everyone. The treatment is still experimental, and its long-term safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Chung-Ang University Hospital

Seoul, Seoulteukbyeolsi, South Korea
Chungnam National University Hospital

Daejeon, Chungcheongnam-do, South Korea
Korea University AnSan Hospital

Ansan, Gyeonggi-do, South Korea
Kyunghee University Medical Center

Seoul, Seoulteukbyeolsi, South Korea
SMG-SNU Boramae Medical Center

Seoul, Seoulteukbyeolsi, South Korea
Seoul National University Hospital

Seoul, Seoulteukbyeolsi, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.